Objectives: The present study aimed to evaluate the efficacy and safety of intravenous metoclopramide for acute migraine treatment.
Materials And Methods: A double-blind, randomized, parallel-group, placebo-controlled trial was carried out in an academic emergency department. After the patients were assessed for eligibility via the International Headache Society criteria for migraines, they were randomized into 10 mg intravenous metoclopramide and normal saline groups. The headache intensity was evaluated using an 11-point numeric rating scale (NRS) score. The primary outcome measure was determined as the median between-group change in the score at the 30th minute. The secondary outcome measures were rescue medication needs, adverse events, and emergency department (ED) revisits after discharge.
Results: A total of 148 patients were randomized into two equal groups with similar baseline characteristics, including the baseline NRS scores (8 points). The median reduction in the NRS scores at the 30th minute was 4 [interquartile range (IQR): 2-6)] in the metoclopramide group and 3 (IQR: 1-4) in the normal saline group [median difference: -1.0, 95% confidence interval (CI): -2.1 to 0.1]. No serious adverse events were observed, and the rescue medication needs were similar in both groups.
Conclusion: No difference was found between intravenous metoclopramide and placebo regarding efficacy and safety in patients with acute migraines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ane.13063 | DOI Listing |
Int Med Case Rep J
December 2024
Faculty of Medicine, Mogadishu University, Mogadishu, Somalia.
Dopamine receptor antagonists like metoclopramide are frequently used in a variety of clinical contexts to treat gastrointestinal disorders and control nausea and vomiting. However, it is associated with a high incidence of extrapyramidal side effects (EPS) in children, including dystonic movements and torticollis. This is the instance of a 9-year-old girl who developed abnormal movements of the neck and tongue, along with torticollis, within 48 hours of receiving intravenous metoclopramide for gastroenteritis.
View Article and Find Full Text PDFAnn Emerg Med
December 2024
Department of Emergency Medicine, Stony Brook University, Stony Brook, NY.
Study Objective: We performed a systematic review and Bayesian network meta-analysis to determine which pharmacologic therapies are relatively more effective and safer for migraine in adult patients who present to the emergency department (ED).
Methods: We searched MEDLINE, Embase, and Web of Science from inception to February 9, 2024. Eligible studies were randomized controlled trials that enrolled adult participants presenting to ED with migraine and compared one pharmacologic therapy to another or placebo.
Front Med (Lausanne)
November 2024
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
World J Hepatol
November 2024
Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva 1205, Switzerland.
Front Pharmacol
November 2024
Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
Background: Feeding intolerance is commonly experienced during enteral feeding, necessitating cessation. Metoclopramide may be given to assist gastric emptying, but patients experience adverse effects and gradual loss of efficacy. Prucalopride, a safer prokinetic, may play a role in gastric emptying.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!